Woman is holding the textile home made face mask used for protection against viruses while walking in the nature. Symbol for protest against regulations or freedom after end of pandemic.
According to results from lab studies, an antibody-based COVID-19 therapy developed by GSK and Vir Biotechnology preserves neutralising activity against the developing BA.2 type of the Omicron coronavirus variant.
The business stated it would reveal preprint data in the coming week, followed by live viral data.
According to the business, the 500 mg dose of sotrovimab is sufficient to maintain action against the BA.2 variation, which is in line with all other variants of concern and interest, based on pseudovirus and substantial pharmacokinetic data.
Sotrovimab is one of the few COVID-19 therapies that has been demonstrated to act against the fast-spreading Omicron form, which has sparked interest. In 2021, it was one of GSK’s best-selling products.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…